Across TCGA pan-cancer cohorts, LINC01017 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01017’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LINC01017 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01017 is over-expressed in tumor.
HNSC are the cancer types where LINC01017 tumor–normal differential expression is most reproducible.